StockData
Monopar Therapeutics logo

Monopar Therapeutics (MNPR) stock

MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$71.06−0.91 (-1.26%)

Close on Nov 17, 2026Market cap $476.97MP/E –Yield –

Monopar Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Monopar Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$22.12M. For fiscal 2025 it was -$16.70M. The highest annual figure on record is -$1.19M in fiscal 2016.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$16.70M–
FY2024Dec 31, 2024-$16.16M–
FY2023Dec 31, 2023-$8.83M–
FY2022Dec 31, 2022-$10.54M–
FY2021Dec 31, 2021-$9.13M–
FY2020Dec 31, 2020-$6.51M–
FY2019Dec 31, 2019-$4.32M–
FY2018Dec 31, 2018-$3.33M–
FY2017Dec 31, 2017-$16.60M–
FY2016Dec 31, 2016-$1.19M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.64M–
Q1 FY2026Mar 31, 2026-$5.23M–
Q4 FY2025Dec 31, 2025-$6.16M–
Q3 FY2025Sep 30, 2025-$4.09M–
Q2 FY2025Jun 30, 2025-$3.23M–
Q1 FY2025Mar 31, 2025-$3.22M–
Q4 FY2024Dec 31, 2024-$11.07M–
Q3 FY2024Sep 30, 2024-$1.57M–
Q2 FY2024Jun 30, 2024-$1.79M–
Q1 FY2024Mar 31, 2024-$1.72M–
Q4 FY2023Dec 31, 2023-$1.91M–
Q3 FY2023Sep 30, 2023-$2.07M–
Q2 FY2023Jun 30, 2023-$2.33M–
Q1 FY2023Mar 31, 2023-$2.53M–
Q4 FY2022Dec 31, 2022-$2.91M–
Q3 FY2022Sep 30, 2022-$2.41M–
Q2 FY2022Jun 30, 2022-$2.76M–
Q1 FY2022Mar 31, 2022-$2.46M–
Q4 FY2021Dec 31, 2021-$2.68M–
Q3 FY2021Sep 30, 2021-$2.46M–
Q2 FY2021Jun 30, 2021-$2.09M–
Q1 FY2021Mar 31, 2021-$1.89M–
Q4 FY2020Dec 31, 2020-$2.26M–
Q3 FY2020Sep 30, 2020-$1.65M–
Q2 FY2020Jun 30, 2020-$1.46M–
Q1 FY2020Mar 31, 2020-$1.14M–
Q4 FY2019Dec 31, 2019-$1.22M–
Q3 FY2019Sep 30, 2019-$759.45K–
Q2 FY2019Jun 30, 2019-$932.11K–
Q1 FY2019Mar 31, 2019-$1.41M–
Q4 FY2018Dec 31, 2018-$926.36K–
Q3 FY2018Sep 30, 2018-$667.53K–
Q2 FY2018Jun 30, 2018-$667.53K–
Q1 FY2018Mar 31, 2018-$897.26K–
Q4 FY2017Dec 31, 2017-$736.80K–
Q3 FY2017Sep 30, 2017-$14.90M–
Q2 FY2017Jun 30, 2017-$594.96K–
Q1 FY2017Mar 31, 2017-$373.84K–

More Monopar Therapeutics figures

See a number that looks wrong?